Replimune

85 articles about Replimune

• Replimune Reports Third Fiscal Quarter 2021 Financial Results and Provides Corporate Update

  2/3/2022

  Replimune Group Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced financial results for the fiscal third quarter ended December 31, 2021 and provided a business update.

• Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors

  1/31/2022

  Replimune Group Inc. today announced Otello Stampacchia, Ph.D., of Omega Funds, has resigned from the company’s Board of Directors.

• Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones

  1/10/2022

  Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, provided a corporate update, highlighting the progress of key programs.

• Replimune Reports Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update

  11/4/2021

  Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, announced financial results for the fiscal second quarter ended September 30, 2021 and provided a business update.

• Replimune to Present at Two Upcoming Investor Conferences - Nov 01, 2021

  11/1/2021

  Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, announced that members from the Replimune management team will present and host investor meetings.

• 

  A Clinical Stage Biotech Without a CMO? Replimune Makes Surprising Cut

  8/26/2021

  While the biotech market sees a high demand for the chief medical officer role, one Massachusetts oncology player has deemed the role completely unnecessary.

• Replimune to Present at Two Upcoming Investor Conferences - Aug 02, 2021

  8/2/2021

  Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, announced that members from the Replimune management team will present and host investor meetings at the following two conferences:

• Replimune to Present at the William Blair Biotech Focus Conference 2021

  7/7/2021

  Replimune Group, Inc. today announced that Robert Coffin, Ph.D., President and Chief Research & Development Officer of Replimune, will participate in a panel titled “Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors” at the William Blair Biotech Focus Conference 2021 taking place virtually on Wednesday July 14, 2021 at 4:20 PM ET.

• Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

  6/3/2021

  High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs

• Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update

  5/20/2021

  Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma

• Replimune Appoints Tanya Lewis as Chief Development Operations Officer

  5/10/2021

  Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced the strengthening of its executive team with the appointment of Tanya Lewis to a newly created position of Chief Development Operations Officer effective May 10, 2021.

• Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab)

  5/5/2021

  - Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced a clinical development update for CERPASS, its registration-directed global randomized Phase 2 clinical trial of RP1 in combination with Libtayo® (cemiplimab)

• Replimune to Host Virtual Investor Event on June 3, 2021Event to begin at 8:00 AM ET

  4/28/2021

  - Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced it will host an investor event to present updated data from its Phase 2 skin cancer cohorts combining RP1 with Opdivo® and data from its Phase 1 study of RP2 alone and in combination with Opdivo.

• Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting

  4/12/2021

  Replimune Group announced data during two presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 10-15, 2021 and May 17-21, 2021.

• Replimune to Present at Three Upcoming Investor Conferences

  3/4/2021

  Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members from the Replimune management team will present and host one-on-one meetings at the following three virtual investor conferences. H.C. Wainwright Global Life Sciences Conference Date: March 9-10, 2021 Pre-Recorded Formal Presentation will be made live: Tuesday, March 9, 2021

• 

  JPM2021, Day 3: Sanofi, Jazz Pharma, Replimune and More

  1/14/2021

  Here’s a look at some of the stories that emerged from the conference on Wednesday.

• Replimune Provides 2020 Year End Review and Overview of Expected 2021 Milestones

  1/11/2021

  RP1; Data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across all studies

• Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/6/2021

  Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually on Tuesday, January 12, 2021 at 5:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at

• Replimune to Participate at the SVB Leerink Oncology 1x1 Day

  11/12/2020

  Replimune Group Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced that members of its senior management team will host investor meetings at the at the SVB Leerink Oncology 1x1 Day being held on Thursday, November 19, 2020.

• Replimune Announces Pricing of Upsized Public Offering - Oct 22, 2020

  10/22/2020

  Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced the pricing of its public offering of 4,687,500 shares of its common stock at a public offering price of $40.00 per share.